open access
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints
Affiliations- Department of Pathophysiology, School of Medicine, University of Split, Split, Croatia
- Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia
- Department of Endocrinology and Diabetology, University Hospital of Split, Split, Croatia
- Department of Cardiovascular and Thoracic Sciences, IRCCS Fondazione Policlinico A Gemelli, Universita Cattolica Sacro Cuore, Rome, Italy
open access
Abstract
Abstract
About this articleTitle
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Short communication
Pages
198-201
Published online
2021-12-06
Page views
4727
Article views/downloads
1610
DOI
10.33963/KP.a2021.0172
Pubmed
Bibliographic record
Kardiol Pol 2022;80(2):198-201.
Authors
Josip A Borovac
Tina Kurir
Ivona Mustapic
Marko Kumric
Josko Bozic
Duska Glavas
Domenico D’Amario
References (13)- de Leeuw AE, de Boer RA. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016; 2(4): 244–255.
- Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019; 18(1): 99.
- Nessler J, Siniarski A, Leszek P, et al. Reviewers. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiol Pol. 2021; 79(3): 363–370.
- McMurray J, Solomon S, Inzucchi S, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413–1424.
- Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139(22): 2528–2536.
- Szarek M, Bhatt DL, Steg PhG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384(2): 117–128.
- Butler J, Filippatos G, Siddiqi TJ, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019; 21(10): 1279–1287.
- Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018; 13(2): 84–91.
- Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019; 170(11): 764–769.
- Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55(5): 503–514.
- Dave CV, Schneeweiss S, Kim D, et al. Sodium-Glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019; 171(4): 248–256.
- Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
